Infliximab therapy for HIV positive Crohn's disease: A case report

Journal of Crohn's and Colitis

Volumn 3, Issue 4, 2009, Pages 302-304

  Habib, Syed F ^a   Hasan, Muhammad Z ^a   Salam, I ^a  

^a WEST WALES GENERAL HOSPITAL   (United Kingdom)

Author keywords

Crohn's disease; HIV; Infliximab

Indexed keywords

INFLIXIMAB; STEROID;

ABDOMINAL PAIN; ADULT; ARTICLE; BIOLOGICAL THERAPY; CASE REPORT; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; STEROID THERAPY; TREATMENT OUTCOME; VOMITING;

EID: 70350620542     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.06.002     Document Type: Article

References (13)

1. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 1 (1995) 129-135
2. Herbein G., Montaner L.J., and Gordon S. Tumor necrosis factor alpha inhibits entry of human immunodeficiency virus type 1 into primary human macrophages: a selective role for the 75-kilodalton receptor. J Virol 70 11 (1996) 7388-7397
3. Whalen C., Horsburgh C.R., Hom D., et al. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 151 (1995) 125-135
4. Odeh M. The role of tumour necrosis factor-alpha in acquired immunodeficiency syndrome. J Intern Med. 228 6 (1990) 549-556
5. Matsuyama T., Hamamoto Y., Soma G., Mizuno D., Yamamoto N., and Kobayashi N. Cytocidal effect of tumor necrosis factor on cells chronically infected with human immunodeficiency virus (HIV): enhancement of HIV replication. J Virol 63 6 (1989) 2504-2509
6. Ito M., Baba M., Sato A., Hirabayashi K., Tanabe F., Shigeta S., et al. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun. 158 1 (1989) 307-127
7. Walker R.E., Spooner K.M., Kelly G., et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 174 (1996) 63-68
8. Elliott M., Maini R., Feldmann M., Kalden J., Antoni C., Smolen J., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344 8930 (1994) 1105-1110
9. Chaudhari U., Romano P., Mulcahy L., Dooley L., Baker D., and Gottlieb A. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 9271 (2001) 1842-1847
10. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multi centre trial. Lancet 9313 (2002) 1187-1193
11. Fidder H.H., Schnitzler F., Ferrante M., Noman M., Katsanos K., Segaert S., et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single center cohort study gut (2008)
12. Cepeda E.J., Williams F.M., Ishimori M.L., Weisman M.H., and Reveille J.D. The use of anti-tumor necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 67 5 (2008) 710-712
13. Beltrán B., Nos P., Bastida G., Iborra M., Hoyos M., and Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 55 11 (2006) 1670-1671